Citi sees $105 as ‘realistic’ takeout price for Esperion after approval

Citi analyst Joel Beatty believes bempedoic acid is likely to be approved and sees potential for Esperion Therapeutics to be acquired post approval in Q1 of 2020. The analyst sees $105 per share as a “realistic” takeout price after a U.S. approval. He believes an FDA panel in the second half of 2019 is likely and that if Esperion announces a panel will not be needed, it would be positive for the shares. In the event U.S. approval is not granted but approval in Europe is still a success, Beatty sees Esperion shares falling to $25. He has a Buy rating on the stock with a $75 price target.

https://thefly.com/landingPageNews.php?id=2891235